Identification | Back Directory | [Name]
LAPAQUISTAT | [CAS]
189060-13-7 | [Synonyms]
TAK-475 CS-1400 LAPAQUISTAT Lapaquistat Acetate Lapaquistat Acetate (TAK-475) Lapaquistat and Lapaquistat Acetate 1-[[(3R,5S)-1-[3-(Acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-4-piperidineacetic acid 2-[1-[2-[1-(3-Acetoxy-2,2-diMethylpropyl)-7-chloro-5(S)-(2,3-diMethoxyphenyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepin-3(R)-yl]acetyl]piperidin-4-yl]acetic acid 4-Piperidineacetic acid, 1-[2-[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]- | [Molecular Formula]
C33H41ClN2O9 | [MOL File]
189060-13-7.mol | [Molecular Weight]
645.14 |
Chemical Properties | Back Directory | [Melting point ]
194-196℃ | [Boiling point ]
826.4±65.0 °C(Predicted) | [density ]
1.246±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
Chloroform (Slightly), DMSO (Slightly), Methanol (Slightly) | [form ]
Solid | [pka]
4.66±0.10(Predicted) | [color ]
White |
Hazard Information | Back Directory | [Uses]
A novel squalene synthase inhibitor | [Biological Activity]
TAK-475 (Lapaquist at acetate) is a potent and selective squalene synthase inhibitor. TAK-475 effectively lowers low-density lipoprotein cholesterol in human. Clinical development of TAK-475 was discontinued due to hepatotoxicity seen in two patients receiving a high dose. | [storage]
Store at -20°C |
|
Company Name: |
LGM Pharma
|
Tel: |
1-(800)-881-8210 |
Website: |
www.lgmpharma.com |
Company Name: |
SPIRO PHARMA
|
Tel: |
|
Website: |
www.spiropharma.com.cn |
Company Name: |
Cckinase, Inc.
|
Tel: |
+1 (732)236-3202 |
Website: |
www.cckinase.com |
Company Name: |
Energy Chemical
|
Tel: |
021-58432009 400-005-6266 |
Website: |
http://www.energy-chemical.com |
|